Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.

Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MP, Chabon JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M, Abu-Akeel M, Plodkowski AJ, Perez-Johnston R, Yoo CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T, Li BT, Alizadeh AA, Diehn M.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.3418.2019. doi: 10.1158/1078-0432.CCR-19-3418. [Epub ahead of print]

PMID:
32046999
2.

The BOND Framework: A Practical Application of Visual Communication Design and Marketing to Advance Evaluation Reporting.

McAlindon K, Neal JW, Neal ZP, Mills KJ, Lawlor J.

Am J Eval. 2019 Jun;40(2):291-305. doi: 10.1177/1098214018771219. Epub 2018 May 17.

PMID:
31631959
3.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro-Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ Sr.

Lung Cancer. 2019 Nov;137:71-75. doi: 10.1016/j.lungcan.2019.09.015. Epub 2019 Sep 18.

PMID:
31557562
4.

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.

Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M.

Clin Cancer Res. 2020 Jan 1;26(1):274-281. doi: 10.1158/1078-0432.CCR-19-1237. Epub 2019 Sep 23.

PMID:
31548347
5.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Nov;137:159-160. doi: 10.1016/j.lungcan.2019.08.020. Epub 2019 Aug 26. No abstract available.

PMID:
31492438
6.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA.

Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.

PMID:
31319993
7.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Jul;133:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15.

PMID:
31200821
8.

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.

Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, Neal JW, Holmes C, Boche D.

Brain. 2019 Jul 1;142(7):2113-2126. doi: 10.1093/brain/awz142.

9.

Just Google it: Measuring schools' use of research evidence with internet search results.

Neal Z, Lawlor J, Neal JW, Mills K, McAlindon K.

Evid Policy. 2019 Jan;15(1):103-123. doi: 10.1332/174426418X15172392413087.

10.

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.

Hirotsu K, Dang TM, Li S, Neal JW, Pugliese S, Subramanian A, Kwong BY.

JAMA Dermatol. 2019 Jul 1;155(7):848-850. doi: 10.1001/jamadermatol.2019.0063. No abstract available.

PMID:
31017625
11.

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.

Sun TY, Sung AW, Neal JW.

J Thorac Oncol. 2019 Apr;14(4):e75-e77. doi: 10.1016/j.jtho.2018.11.030. No abstract available.

12.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

Riess JW, Kong CS, West RB, Padda SK, Neal JW, Wakelee HA, Le QT.

Clin Lung Cancer. 2019 May;20(3):e356-e361. doi: 10.1016/j.cllc.2018.12.005. Epub 2018 Dec 21.

PMID:
30773448
13.
14.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.

Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.

Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.

PMID:
30762593
15.

Multiple Audiences for Encouraging Research Use: Uncovering a Typology of Educators.

Neal JW, Mills KJ, McAlindon K, Neal ZP, Lawlor JA.

Educ Adm Q. 2019 Feb;55(1):154-181. doi: 10.1177/0013161X18785867. Epub 2018 Jun 26.

16.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

17.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV.

J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

18.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.

Myall NJ, Henry S, Wood D, Neal JW, Han SS, Padda SK, Wakelee HA.

Clin Lung Cancer. 2019 Mar;20(2):e208-e217. doi: 10.1016/j.cllc.2018.10.003. Epub 2018 Oct 23.

19.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.

Nguyen KH, Stehr H, Zhou L, Nguyen AH, Hiep PN, Van Cau N, Duy PC, Thorp R, Wakelee HA, Diehn M, Neal JW.

J Glob Oncol. 2018 Nov;4:1-9. doi: 10.1200/JGO.18.00086.

20.

Meningeal inflammation and cortical demyelination in acute multiple sclerosis.

Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, Magliozzi R, Allen I, McDonnell G, Kee R, Naughton M, Fitzgerald DC, Reynolds R, Neal JW, Howell OW.

Ann Neurol. 2018 Dec;84(6):829-842. doi: 10.1002/ana.25365. Epub 2018 Nov 30.

21.

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.

Sun TY, Niu X, Chakraborty A, Neal JW, Wakelee HA.

J Thorac Oncol. 2019 Feb;14(2):e21-e24. doi: 10.1016/j.jtho.2018.08.2030. Epub 2018 Sep 11. No abstract available.

22.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW.

Oncologist. 2019 Jun;24(6):836-843. doi: 10.1634/theoncologist.2018-0264. Epub 2018 Aug 20.

23.

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.

Wang SXY, Lei L, Guo HH, Shrager J, Kunder CA, Neal JW.

Lung Cancer. 2018 Aug;122:187-191. doi: 10.1016/j.lungcan.2018.06.019. Epub 2018 Jun 15.

PMID:
30032829
24.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

25.

Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.

Zweig JR, Neal JW.

J Clin Oncol. 2018 Sep 10;36(26):2677-2679. doi: 10.1200/JCO.2018.78.8554. Epub 2018 Jun 25. No abstract available.

PMID:
29939839
26.

CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis.

Griffiths MR, Botto M, Morgan BP, Neal JW, Gasque P.

Immunology. 2018 Nov;155(3):346-355. doi: 10.1111/imm.12974. Epub 2018 Jul 11.

27.

The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Bedoui Y, Neal JW, Gasque P.

J Neuroimmune Pharmacol. 2018 Sep;13(3):309-329. doi: 10.1007/s11481-018-9793-6. Epub 2018 Jun 16. Review.

PMID:
29909495
28.

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.

Chin AL, Kumar KA, Guo HH, Maxim PG, Wakelee H, Neal JW, Diehn M, Loo BW Jr, Gensheimer MF.

Clin Lung Cancer. 2018 Sep;19(5):e581-e588. doi: 10.1016/j.cllc.2018.04.003. Epub 2018 Apr 19.

PMID:
29759331
29.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

30.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ.

Lung Cancer. 2018 Mar;117:44-49. doi: 10.1016/j.lungcan.2018.01.010. Epub 2018 Feb 3.

31.

Supporting mental health providers: The feasibility and promise of a virtual professional learning community.

Mehta TG, Atkins MS, Neal JW, Walden AL.

Evid Based Pract Child Adolesc Ment Health. 2018;3(4):236-251. doi: 10.1080/23794925.2018.1486687. Epub 2018 Jul 19. No abstract available.

32.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors.

Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA.

J Thorac Imaging. 2018 May;33(3):176-183. doi: 10.1097/RTI.0000000000000310.

33.

What Makes Research Useful for Public School Educators?

Neal JW, Neal ZP, Lawlor JA, Mills KJ, McAlindon K.

Adm Policy Ment Health. 2018 May;45(3):432-446. doi: 10.1007/s10488-017-0834-x.

34.

We didn't say that: Challenges in the Public Dissemination of a Research Finding with Controversial Implications.

Neal ZP, Neal JW.

Am J Community Psychol. 2017 Dec;60(3-4):424-429. doi: 10.1002/ajcp.12175. Epub 2017 Sep 18.

PMID:
28921584
35.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M.

Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.

36.

Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.

Bui N, Henry S, Wood D, Wakelee HA, Neal JW.

JCO Clin Cancer Inform. 2017;1. doi: 10.1200/CCI.16.00055. Epub 2017 Mar 13. No abstract available.

37.

Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.

Gao RW, Berry MF, Kunder CA, Khuong AA, Wakelee H, Neal JW, Backhus LM, Shrager JB.

J Thorac Cardiovasc Surg. 2017 Dec;154(6):2092-2099.e2. doi: 10.1016/j.jtcvs.2017.07.034. Epub 2017 Aug 1.

38.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.

Gensheimer MF, Hong JC, Chang-Halpenny C, Zhu H, Eclov NCW, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, Hara WY, Quon A, Maxim PG, Graves EE, Olson MR, Diehn M, Loo BW Jr.

Radiother Oncol. 2017 Nov;125(2):338-343. doi: 10.1016/j.radonc.2017.08.007. Epub 2017 Aug 19.

PMID:
28830717
39.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.

Choi CYH, Wakelee HA, Neal JW, Pinder-Schenck MC, Yu HM, Chang SD, Adler JR, Modlin LA, Harsh GR, Soltys SG.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):16-21. doi: 10.1016/j.ijrobp.2017.04.041. Epub 2017 May 6.

PMID:
28816142
40.

Network Analysis in Community Psychology: Looking Back, Looking Forward.

Neal ZP, Neal JW.

Am J Community Psychol. 2017 Sep;60(1-2):279-295. doi: 10.1002/ajcp.12158. Epub 2017 Aug 17. Review.

41.

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

El-Deiry WS, Taylor B, Neal JW.

Am Soc Clin Oncol Educ Book. 2017;37:e8-e15. doi: 10.14694/EDBK_175524.

42.

Novel systemic therapy against malignant pleural mesothelioma.

Mancuso MR, Neal JW.

Transl Lung Cancer Res. 2017 Jun;6(3):295-314. doi: 10.21037/tlcr.2017.06.01. Review.

43.

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis.

Loveless S, Neal JW, Howell OW, Harding KE, Sarkies P, Evans R, Bevan RJ, Hakobyan S, Harris CL, Robertson NP, Morgan BP.

Brain Pathol. 2018 Jul;28(4):507-520. doi: 10.1111/bpa.12546. Epub 2017 Jul 30.

PMID:
28707765
44.

Evolving concepts of chronic traumatic encephalopathy as a neuropathological entity.

Ling H, Neal JW, Revesz T.

Neuropathol Appl Neurobiol. 2017 Oct;43(6):467-476. doi: 10.1111/nan.12425. Review.

PMID:
28664614
45.

The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.

Chuang JC, Neal JW.

Cancer. 2017 Aug 1;123(15):2798-2801. doi: 10.1002/cncr.30718. Epub 2017 May 4. No abstract available.

46.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

47.

Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.

Costa HA, Neal JW, Bustamante CD, Zehnder JL.

Mol Diagn Ther. 2017 Aug;21(4):431-436. doi: 10.1007/s40291-017-0275-y.

48.

Corrigendum to "The role of primary infection of Schwann cells in the aetiology of infective inflammatory neuropathies" [J Infect 73 (2016) 402-418].

Neal JW, Gasque P.

J Infect. 2017 May;74(5):525. doi: 10.1016/j.jinf.2017.02.003. Epub 2017 Feb 27. No abstract available.

PMID:
28245429
49.

Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players.

Ling H, Morris HR, Neal JW, Lees AJ, Hardy J, Holton JL, Revesz T, Williams DD.

Acta Neuropathol. 2017 Mar;133(3):337-352. doi: 10.1007/s00401-017-1680-3. Epub 2017 Feb 15.

50.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW.

J Thorac Oncol. 2017 May;12(5):833-842. doi: 10.1016/j.jtho.2017.01.023. Epub 2017 Feb 4.

Supplemental Content

Support Center